European central nervous system disorders specialist Neuraxpharm is continuing expansion in the therapeutic area after striking a deal to acquire the narcolepsy brands Provigil (modafinil) and Nuvigil (armodafinil) “in most markets outside of the US.”
Neuraxpharm Picks Up A Pair Of Narcolepsy Drugs As Deal Frenzy Continues Apace
Deal Includes Provigil And Nuvigil Brands In ‘Most’ Non-US Markets
Neuraxpharm’s business development team remains busy entering the new year, after signing yet another strategic deal – this time to grow the firm’s core presence in CNS disorder drugs.
More from Deals
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.
• By
Cipla has bolstered its ophthalmology portfolio and increased its global offering after chalking up an agreement to add Formosa Pharmaceuticals’ USFDA-approved clobetasol propionate 0.05% ophthalmic suspension.
• By
Along with financial backing from the Canadian government, a fresh, decade-long partnership with Sandoz Canada will allow Delpharm to carry out modernization plans for its manufacturing facility in Boucherville, securing the local supply chain for sterile injectable medicines.
More from Generics Bulletin
• By
Off-patent drug trade groups expressed their concerns that personnel and expertise cuts will affect the agency’s ability to review and approve generics and biosimilars.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.